Donald Trump has already been fairly radical as the President. He appointed cabinet members outside the beltway, hand-picked folks who the insiders would scoff at and pushed them to the front. He’s been a job creator, negotiating and striking good faith deals with Ford, GM, US Steel, and Carrier to name a few. And he’s wielded the executive pen daily, signing orders to stop NAFTA, impose a short-term ban on refugees, and starting the process of building a southern border wall.
All these seem like radical changes after eight years of President Obama who was staunchly in the other direction.
So it should come as no surprise that another radical agenda on Trump’s plate is picking a new FDA advisor, who might be more lenient on medical marijuana.
Marijuana has proven its effectiveness in healing or relieving all kinds of ailments. Stacks of studies back up the claims that MMJ will offer millions relief.
Trump is considering two more outsiders for the FDA. Balaji Srinivasan and Jim O’Neil both have talked with Trump about leading an agency that neither is fond of, at least in its current state.
And while a Srinivasan nomination would certainly be in the same mold of Trump’s previous picks – most of his nominees have been critical of the agencies they are about to lead – it’s the potential selection of O’Neill that should excite cannabis and medical marijuana supporters more.
The Anti Media noted:
As a member of the Board of Directors of the Coalition for Cannabis Policy Reform, O’Neill has been fighting for weed legalization for years. The Coalition is known for having helped to legalize the plant in the Golden State.
O’Neill is both a vocal supporter of marijuana legalization and an advocate of a more lenient FDA. He has also talked about the importance of implementing dramatic FDA reforms that would permit Americans the choice to “start using [drugs], at their own risk.”
He is also a board member at the Seasteading Institute, an organization that seeks to create new societies at sea and away from current governments. This organization has been linked to libertarian movements in the past.
O’Neil, if picked, will certainly shake up the MMJ world. His libertarian leanings and his distrust of the system that doesn’t give Americans choice with their health care products might come through if he directs the FDA.
Imagine a world where the FDA is controlled by an advocate of legal marijuana. If this were to happen, it would change the landscape of the entire country. America could no longer wage a war on drugs that disproportionately lands young African-Americans in jail. Police would have more time and energy to investigate crimes not related to marijuana as
crime organizations’ cash flow would dry up in as MMJ became a legal substance.
Additionally, local and state economies could reformat their budgets to account for a surplus in tax dollars associated with MMJ, using those tax dollars to invest in education and public schools, like Colorado did when it legalized medicinal and recreational marijuana.
And most importantly, people across the nation could choose to use MMJ to treat chronic pain. They could pay market value for it or choose to grow it themselves. Patients receiving chemo and radiation could restore their appetites and use their diets to help ward off the sickness currently ravaging their bodies.
So keep an eye out for a shift at the FDA. It could affect the rest of the country.